RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+9.58%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$5.45B
AUM Growth
+$5.45B
(+0.56%)
Cap. Flow
+$83.4M
Cap. Flow
% of AUM
1.53%
Top 10 Holdings %
Top 10 Hldgs %
47.61%
Holding
95
New
15
Increased
22
Reduced
33
Closed
14
Top Buys
| 1 |
Gilead Sciences
GILD
|
$181M |
| 2 |
OSH
Oak Street Health, Inc.
OSH
|
$142M |
| 3 |
Annexon
ANNX
|
$104M |
| 4 |
Nurix Therapeutics
NRIX
|
$90.5M |
| 5 |
Kymera Therapeutics
KYMR
|
$88.3M |
Top Sells
| 1 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
$162M |
| 2 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
$157M |
| 3 |
BioNTech
BNTX
|
$127M |
| 4 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
$64.2M |
| 5 |
CryoPort
CYRX
|
$55M |
Sector Composition
| 1 | Healthcare | 92.54% |
| 2 | Financials | 0.5% |
| 3 | Technology | 0% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Fate Therapeutics
FATE
$120M
| $505M | 9.27% | 12,629,737 | – | – |
|
2
Amicus Therapeutics
FOLD
$2.34B
| $326M | 5.98% | 23,075,807 -1,868,888 | -7% | -$26.4M |
|
|
IMMU
3
DELISTED
Immunomedics Inc
IMMU
| $275M | 5.05% | 3,234,934 -254,966 | -7% | -$21.7M |
|
4
argenx
ARGX
$43.6B
| $259M | 4.76% | 988,468 -46,400 | -4% | -$12.2M |
|
|
IGMS
5
DELISTED
IGM Biosciences
IGMS
| $253M | 4.64% | 3,425,455 +281,455 | +9% | +$20.8M |
|
|
DCPH
6
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $245M | 4.5% | 4,774,918 -204,023 | -4% | -$10.5M |
|
7
ADC Therapeutics
ADCT
$345M
| $210M | 3.85% | 6,353,094 +827,224 | +15% | +$27.3M |
|
|
ALLK
8
DELISTED
Allakos
ALLK
| $198M | 3.63% | 2,425,560 -193,520 | -7% | -$15.8M |
|
|
9
Gilead Sciences
GILD
$140B
| $181M | 3.33% | +2,869,962 | New | +$181M |
|
|
OSH
10
DELISTED
Oak Street Health, Inc.
OSH
| $142M | 2.6% | +2,652,411 | New | +$142M |
|
|
11
Annexon
ANNX
$226M
| $104M | 1.91% | +3,442,122 | New | +$104M |
|
|
EPZM
12
DELISTED
Epizyme, Inc
EPZM
| $99.2M | 1.82% | 8,311,633 -173,972 | -2% | -$2.08M |
|
|
ONEM
13
DELISTED
1Life Healthcare, Inc. Common Stock
ONEM
| $94.9M | 1.74% | 3,344,694 +334,010 | +11% | +$9.47M |
|
14
Biogen
BIIB
$19.4B
| $92.9M | 1.71% | 327,447 +165,147 | +102% | +$46.8M |
|
|
15
Nurix Therapeutics
NRIX
$714M
| $90.5M | 1.66% | +2,593,570 | New | +$90.5M |
|
16
Atara Biotherapeutics
ATRA
$84.6M
| $89.9M | 1.65% | 6,938,870 +95,500 | +1% | +$1.24M |
|
|
17
Kymera Therapeutics
KYMR
$2.95B
| $88.3M | 1.62% | +2,732,660 | New | +$88.3M |
|
18
Sanofi
SNY
$121B
| $87.4M | 1.61% | 1,743,048 +517,548 | +42% | +$26M |
|
|
19
BioNTech
BNTX
$24B
| $85.5M | 1.57% | 1,235,645 -1,833,519 | -60% | -$127M |
|
20
Stoke Therapeutics
STOK
$1.08B
| $85.4M | 1.57% | 2,549,506 +47,200 | +2% | +$1.58M |
|
21
Beam Therapeutics
BEAM
$1.66B
| $81.9M | 1.5% | 3,327,262 -29,696 | -0.9% | -$731K |
|
22
Zentalis Pharmaceuticals
ZNTL
$122M
| $79.5M | 1.46% | 2,432,408 +771,203 | +46% | +$25.2M |
|
23
Pliant Therapeutics
PLRX
$101M
| $76.8M | 1.41% | 3,391,757 -18,900 | -0.6% | -$428K |
|
24
Replimune Group
REPL
$422M
| $76.7M | 1.41% | 3,330,999 +226,806 | +7% | +$5.22M |
|
25
Repare Therapeutics
RPTX
$71.7M
| $74M | 1.36% | 2,404,974 +18,800 | +0.8% | +$578K |
|